Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Warfarin in Healthy Male and Female Adults

NCT01477424 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.

NCT NCT01477424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01477424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Warfarin in Healthy Male and Female Adults
Lead sponsor
Vifor Pharma
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2011
Completion date
February 29, 2012
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug interaction potentiation